Abstract：
UNASSIGNED: Lactate dehydrogenase (LDH) is involved in the Warburg effect. Elevated serum LDH is a prognostic marker for metastatic solid cancer.
UNASSIGNED: To investigate the prognostic impact of serum LDH in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors (ICIs).
UNASSIGNED: This retrospective study included 129 patients treated with ICIs between 2017 and 2023. The effects of pretreatment LDH, LDH at 3 months, and change in LDH during the first 3 months (ΔLDH) on overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression model.
UNASSIGNED: The 1-year PFS and OS rates for high and low groups were 6.0% and 30.1% for pretreatment LDH (p = 0.044), 25.7% and 38.3% for on-treatment LDH (p = 0.079), and 14.3% and 38.7% for ΔLDH (p = 0.008), as well as 42.1% and 60.9% for pretreatment LDH (p = 0.109), 56.0% and 80.5% (p < 0.001) for on-treatment LDH, and 31.0% and 81.0% for ΔLDH (p < 0.001), respectively. ΔLDH was an independent prognostic factor for both PFS and OS.
UNASSIGNED: ΔLDH can be used to predict ICI treatment outcomes and as a marker in deciding to continue ICI therapy.
UNASSIGNED: To investigate the prognostic impact of serum LDH in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors (ICIs).
UNASSIGNED: This retrospective study included 129 patients treated with ICIs between 2017 and 2023. The effects of pretreatment LDH, LDH at 3 months, and change in LDH during the first 3 months (ΔLDH) on overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression model.
UNASSIGNED: The 1-year PFS and OS rates for high and low groups were 6.0% and 30.1% for pretreatment LDH (p = 0.044), 25.7% and 38.3% for on-treatment LDH (p = 0.079), and 14.3% and 38.7% for ΔLDH (p = 0.008), as well as 42.1% and 60.9% for pretreatment LDH (p = 0.109), 56.0% and 80.5% (p < 0.001) for on-treatment LDH, and 31.0% and 81.0% for ΔLDH (p < 0.001), respectively. ΔLDH was an independent prognostic factor for both PFS and OS.
UNASSIGNED: ΔLDH can be used to predict ICI treatment outcomes and as a marker in deciding to continue ICI therapy.
摘要：
■乳酸脱氢酶（LDH）参与Warburg效应。血清LDH升高是转移性实体癌的预后标志物。
■探讨血清LDH对接受免疫检查点抑制剂（ICIs）治疗的头颈部鳞状细胞癌患者预后的影响。
■这项回顾性研究包括2017年至2023年期间接受ICIs治疗的129例患者。预处理LDH的影响，LDH在3个月，使用Kaplan-Meier方法和Cox回归模型分析前3个月LDH（ΔLDH）对总生存期（OS）和无进展生存期（PFS）的变化。
■高组和低组的1年PFS和OS率分别为治疗前LDH的6.0％和30.1％（p=0.044），治疗中LDH分别为25.7%和38.3%（p=0.079），ΔLDH为14.3%和38.7%(p=0.008)，以及预处理LDH的42.1%和60.9%(p=0.109)，治疗中LDH分别为56.0%和80.5%(p<0.001)，ΔLDH为31.0%和81.0%(p<0.001)，分别。ΔLDH是PFS和OS的独立预后因素。
■ΔLDH可用于预测ICI治疗结果，并作为决定继续ICI治疗的标志。
■探讨血清LDH对接受免疫检查点抑制剂（ICIs）治疗的头颈部鳞状细胞癌患者预后的影响。
■这项回顾性研究包括2017年至2023年期间接受ICIs治疗的129例患者。预处理LDH的影响，LDH在3个月，使用Kaplan-Meier方法和Cox回归模型分析前3个月LDH（ΔLDH）对总生存期（OS）和无进展生存期（PFS）的变化。
■高组和低组的1年PFS和OS率分别为治疗前LDH的6.0％和30.1％（p=0.044），治疗中LDH分别为25.7%和38.3%（p=0.079），ΔLDH为14.3%和38.7%(p=0.008)，以及预处理LDH的42.1%和60.9%(p=0.109)，治疗中LDH分别为56.0%和80.5%(p<0.001)，ΔLDH为31.0%和81.0%(p<0.001)，分别。ΔLDH是PFS和OS的独立预后因素。
■ΔLDH可用于预测ICI治疗结果，并作为决定继续ICI治疗的标志。
